Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
NCT01573338 · Bayer · PHASE1/PHASE2 · terminated · last registry update 2021-04-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Bayer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CDK1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-12-22Also stopped (terminated): Cyclacel Pharmaceuticals, Inc., seliciclib + placebo (NCT00372073)
- 2021-11-04Also stopped (terminated): Shlomo Melmed, MD, R-roscovitine (NCT02160730)
- 2021-10-29Results posted on the registry: Shlomo Melmed, MD, R-roscovitine (NCT02160730)
- 2021-09-28Results posted on the registry: National Cancer Institute (NCI), Zotiraciclib (TG02) + Temozolomide (TMZ) (NCT02942264)
- 2021-07-15Results posted on the registry: Sumitomo Pharma America, Inc., Alvocidib + Cytarabine (NCT02520011)
- 2021-05-24Results posted on the registry: Sumitomo Pharma America, Inc., Alvocidib + Cytarabine (NCT03298984)
- 2021-03-01Results posted on the registry: Merck Sharp & Dohme LLC, pembrolizumab + dinaciclib (NCT02684617)
- 2021-03-01Also stopped (terminated): Merck Sharp & Dohme LLC, pembrolizumab + dinaciclib (NCT02684617)
- 2020-11-12Also stopped (withdrawn): M.D. Anderson Cancer Center, Alvocidib Hydrochloride + Decitabine (NCT04493099)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision